Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
The classic form of Pelizaeus-Merzbacher disease (PMD) is the infantile form of PMD.
Features include very common findings: Nystagmus, Delayed speech and language development, Ataxia, and Mild intellectual disability and others; and common findings: Low muscle tone (hypotonia), Spasticity, Spastic tetraparesis, and Dystonia and others. 27 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 16 | Delayed speech and language development, Ataxia, Mild intellectual disability |
Biomarker and diagnostic research for Pelizaeus-Merzbacher disease, classic form has been reported in the published literature.
Phenotype severity distribution: 9 very common features, 15 common features.
Estimated prevalence: 1-9 in 1,000,000 (Rare).
No clinical trials have been registered for Pelizaeus-Merzbacher disease, classic form.
48 publications have been identified in PubMed for Pelizaeus-Merzbacher disease, classic form. Research spans Review / Meta-Analysis (28%), Basic Science / Preclinical (28%), and Case Report / Case Series (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 12 | 28% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 4:52 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Pelizaeus-Merzbacher disease, classic form
Muscles | 2 | Low muscle tone (hypotonia), Axial hypotonia |
Eyes | 1 | Nystagmus |
Laboratory research
12 |
28% |
Patient case studies | 8 | 19% |
Testing and diagnosis research | 4 | 9% |
New treatment approaches | 4 | 9% |
Disease patterns and progression | 2 | 5% |
Clinical study results | 1 | 2% |
Aynekin B (2026). [PMID: 41672381](https://pubmed.ncbi.nlm.nih.gov/41672381/). *Biochim Biophys Acta Mol Basis Dis*. [Basic Science / Preclinical]
Le A (2026). [PMID: 41518854](https://pubmed.ncbi.nlm.nih.gov/41518854/). *Pediatr Neurol*. [Basic Science / Preclinical]
Sabbagh Q (2026). [PMID: 42063611](https://pubmed.ncbi.nlm.nih.gov/42063611/). *Neurol Genet*. [Case Report / Case Series]
Sevagamoorthy A (2026). [PMID: 42176404](https://pubmed.ncbi.nlm.nih.gov/42176404/). *Mol Genet Metab*. [Epidemiology / Natural History]
Kagiava A (2026). [PMID: 42134074](https://pubmed.ncbi.nlm.nih.gov/42134074/). *EBioMedicine*. [Review / Meta-Analysis]
Cusack SV (2026). [PMID: 42060827](https://pubmed.ncbi.nlm.nih.gov/42060827/). *Dev Med Child Neurol*. [Gene Therapy / Novel Therapeutics]
Kagiava A (2026). [PMID: 41289961](https://pubmed.ncbi.nlm.nih.gov/41289961/). *EBioMedicine*. [Gene Therapy / Novel Therapeutics]
Erdoğan HA (2026). [PMID: 41777520](https://pubmed.ncbi.nlm.nih.gov/41777520/). *Noro Psikiyatr Ars*. [Diagnostic / Biomarker]
Vorst GHJ (2026). [PMID: 41719755](https://pubmed.ncbi.nlm.nih.gov/41719755/). *Neuroimage Clin*. [Epidemiology / Natural History]
Gutierrez-Quintana R (2026). [PMID: 41701830](https://pubmed.ncbi.nlm.nih.gov/41701830/). *Proc Natl Acad Sci U S A*. [Basic Science / Preclinical]
AI-curated news mentioning Pelizaeus-Merzbacher disease, classic form
Updated Feb 17, 2026
A study identifies a canine PLP1 missense variant that influences oligodendrocyte maturation in connatal and classical Pelizaeus-Merzbacher disease. This research could provide insights into the mechanisms underlying these forms of the disease.